

Electronic Acknowledgement Receipt	
EFS ID:	6182781
Application Number:	10542501
International Application Number:	
Confirmation Number:	5801
Title of Invention:	Quaternary antimuscarinic compounds for the treatment of bladder diseases
First Named Inventor/Applicant Name:	Ronald W Wood
Correspondence Address:	Michael L Goldman Nixon Peabody Clinton Square PO Box 31051 Rochester NY 14603-1051 US - -
Filer:	Michael L. Goldman
Filer Authorized By:	
Attorney Docket Number:	176/61373
Receipt Date:	01-OCT-2009
Filing Date:	10-JAN-2006
Time Stamp:	16:07:04
Application Type:	U.S. National Stage under 35 USC 371

Payment information:	
Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$735

RAM confirmation Number	2419				
Deposit Account	141138				
Authorized User					
<p>The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:</p> <p>Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)</p>					
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		20091001_Amendment_176_61373.pdf	123101 36acbd877e88d25d8e29e8d57e658a9e9fd8987	yes	16
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment/Req. Reconsideration-After Non-Final Reject		1	1	
	Claims		2	10	
	Applicant Arguments/Remarks Made in an Amendment		11	16	
Warnings:					
Information:					
2	Extension of Time	20091001_Petition_for_Three_Month_Extension_of_Time_176_61373.pdf	66065 2856b87e1646c50d7459f45959b93e29c5d45369	no	1
Warnings:					
Information:					
3	Foreign Reference	WO98000133.pdf	1362228 083696bb0d91a41db87deb9709d4cca491d7b203	no	30
Warnings:					
Information:					
4	Foreign Reference	WO98000138.pdf	1278121 fb5995be157a7ea1513e0e1bb4b519948b0b20f3	no	29
Warnings:					
Information:					
5	NPL Documents	Abood_The_Psychotomimetic_1968.pdf	1821666 00d5eedff729d6fda25c09b1e12311e640055664	no	22

Warnings:					
Information:					
6	NPL Documents	Abood_Anticholinergics_1982.pdf	1233067	no	18
			a67d23e0ca1948354f1aa283fa48112784b537eb		
Warnings:					
Information:					
7	NPL Documents	Baumgold_Chemical_1975.pdf	842612	no	9
			2560e04e6e0eb4c1978ab775a5a3ad97acebc91e		
Warnings:					
Information:					
8	NPL Documents	Baumgold_Studies_1977.pdf	991905	no	10
			03bb52cb671bdcad0f9122bafc0cad367bc9c45		
Warnings:					
Information:					
9	NPL Documents	Bonner_Identification_1987.pdf	609478	no	6
			6b43022a897eb56cdcd52e2eb8cda86d1181d70a		
Warnings:					
Information:					
10	NPL Documents	Bonner_Cloning_1988.pdf	625506	no	8
			7b29c681764bf0a588a3637d204b856159031204		
Warnings:					
Information:					
11	NPL Documents	Brown_Atropine.pdf	1772689	no	18
			d987383c06ed2f06471ea11e274ec2f961072eca		
Warnings:					
Information:					
12	NPL Documents	Buckley_Antagonist.pdf	714753	no	8
			f79f4bc7b66a7b09e6a9a5397eed49b92b754372		
Warnings:					
Information:					
13	NPL Documents	Carroll_Probes.pdf	489048	no	5
			df7205875d22687aa18315912fd255343dd7799b		
Warnings:					
Information:					
14	NPL Documents	Carter_Analogues.pdf	1003935	no	10
			692fc6d0f475e875daaa5bc9326fc20ab0d6e721		

Warnings:					
Information:					
15	NPL Documents	Cereda_Synthesis.pdf	599792	no	6
			413ae143e1c974c740dd06c66b97daf74f77cf3b		
Warnings:					
Information:					
16	NPL Documents	Comer_Clocinnamox.pdf	480927	no	6
			31636610bbccfd8718d2cb904049afaa15fcd94b		
Warnings:					
Information:					
17	NPL Documents	Connor_Early.pdf	237954	no	3
			4f02dd5b9ba6e5e9b189827ca6c9f9b009567d5e		
Warnings:					
Information:					
18	NPL Documents	Davies_Novel.pdf	340531	no	5
			52992bf3ad4cd99192b34491196cea5a7f375c5f		
Warnings:					
Information:					
19	NPL Documents	Deckers_The_Chemistry.pdf	391725	no	6
			208eeda550bd21b81aa3fd74ba85b4fe6f42fb15		
Warnings:					
Information:					
20	NPL Documents	Delforge_Noninvasive_1990.pdf	961957	no	11
			963d41e947f14f37bd1f92384ac00c394f77e13a		
Warnings:					
Information:					
21	NPL Documents	Delforge_Quantification_1993.pdf	915544	no	11
			71a38ace812e48857e64e91a1b916597cb3820ff		
Warnings:					
Information:					
22	NPL Documents	Ehlert_The_Quaternary.pdf	537836	no	6
			15a31973c5fe43bff64127acb30a5877c1c6bc24		
Warnings:					
Information:					
23	NPL Documents	Gibson_The_Distribution.pdf	599508	no	6
			c09c62e1e6ee164e3b295e920694ce7029fc59cd		

Warnings:					
Information:					
24	NPL Documents	Goldstein_Principles.pdf	496902	no	8
			34bf978b935d69564a299de7bd3645da28254033		
Warnings:					
Information:					
25	NPL Documents	Gordon_Distance.pdf	548580	no	7
			c6e5d16e07c4283b8e45a5b5473ba32978ca92ea		
Warnings:					
Information:					
26	NPL Documents	Griffin_Kinetics.pdf	487207	no	5
			5e6115e438ffdf2e7a46077799ad0f5ae46889b4		
Warnings:					
Information:					
27	NPL Documents	Gross_Drug.pdf	1068270	no	9
			7d6449dca847e8ae2121142c94bb57908968d431		
Warnings:					
Information:					
28	NPL Documents	Guan_A_Minipig.pdf	620665	no	7
			06746c047cfb41dc6ba4e44e2c296bd0f41a2e28		
Warnings:					
Information:					
29	NPL Documents	Haeusler_Drug.pdf	747885	no	14
			3127f2abdb005a55f4a4f6418bdbbd5f46110e0c		
Warnings:					
Information:					
30	NPL Documents	Kaiser_Synthesis_1992.pdf	1036161	no	10
			6a6569bbb6dd62e6989a5963aba165733d7baeeb		
Warnings:					
Information:					
31	NPL Documents	Kaiser_Synthesis_1993.pdf	637997	no	7
			2c60a203b9e023f79157827d3aae0c20d0deb19f		
Warnings:					
Information:					
32	NPL Documents	Kondo_A_Study_Abstract_1993.pdf	389001	no	6
			13b9eebe4c98144167a5e2e8a9b35c3bc0395272		

Warnings:					
Information:					
33	NPL Documents	Kondo_Muscarinic_1995.pdf	254559	no	4
			0e968f4edd5ee2e4cb8c2ab26b0c3e53656d53df		
Warnings:					
Information:					
34	NPL Documents	Krishnan_A_Double_Abstract.pdf	183338	no	2
			2b69d8680f98140017b1dd4fd683d5ae8f1636cf		
Warnings:					
Information:					
35	NPL Documents	Newberry_Pharmacological.pdf	747374	no	10
			bbbc6e713e0ad6bdb23d15fbc0b0b65d50384b8e6		
Warnings:					
Information:					
36	NPL Documents	Nordvall_Binding.pdf	902583	no	10
			ea6110d802d58d5fb59b800dc5b3f42bfe08fccb		
Warnings:					
Information:					
37	NPL Documents	Parsons_Epithelial.pdf	410578	no	4
			755e3eee7f47b73e2621c057d005b48f4f630d03		
Warnings:					
Information:					
38	NPL Documents	Peterson_Mini.pdf	584772	no	9
			f100be1026aa8e298061638430d8a547a702a5d3		
Warnings:					
Information:					
39	NPL Documents	Roberts_A_Pharmacological.pdf	683384	no	9
			8667b2efd408464a2b2979afc95f5687bfe474a0		
Warnings:					
Information:					
40	NPL Documents	Rzeszotarski_Analogues.pdf	595612	no	4
			b76c56b1fa52b36085f8c3a82d51d84388c8a96f		
Warnings:					
Information:					
41	NPL Documents	Sebastian_14Beta.pdf	700639	no	7
			2e67183bed667f07cfa9640bff13aed49a728010		

Warnings:					
Information:					
42	NPL Documents	Sethia_An_Animal.pdf	309270	no	4
			204ca1d1cc4525994eac34e1a068cdb59b9bfc62		
Warnings:					
Information:					
43	NPL Documents	Shishido_Muscarinia_Abstract.pdf	131986	no	2
			44aaacecf6be3965f7600454a8de3fed09c9a545		
Warnings:					
Information:					
44	NPL Documents	Sternbach_Antispasmodics.pdf	654608	no	4
			d1c649e579bb0623f0769c2ad0fe38a719462e5c		
Warnings:					
Information:					
45	NPL Documents	Thomas_Irreversible.pdf	265756	no	5
			d29b3eb1b2d4e3e075a9831c1ae7a7fdb9f0d601		
Warnings:					
Information:					
46	NPL Documents	Waelbroeck_Binding.pdf	667122	no	8
			f0c4acca463d207e890c5ae343c20a2b661a68cd		
Warnings:					
Information:					
47	Transmittal Letter	20091001_Supplemental_Information_Disclosure_Statement_176_61373.pdf	59644	no	1
			11c0b068d034e9f745085b44c9322ce5942cda37		
Warnings:					
Information:					
48	Information Disclosure Statement (IDS) Filed (SB/08)	20091001_PTO_SB_08A_176_61373.pdf	129730	no	4
			0cda16446597e26a60a5af240b5d14f897f7b234		
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
49	Fee Worksheet (PTO-875)	fee-info.pdf	31732	no	2
			fef96910338e1eaa8687733a4488846b60db7ff3		
Warnings:					
Information:					
Total Files Size (in bytes):			31345303		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.